All In Biotech

Drug Trial Radar · NCT00805467

Open-Label, Multicenter Extension Study for Patients Completing Treatment Phase of a Rigel-Sponsored R935788 Studies

An Open-Label, Multicenter Extension Study to Evaluate the Safety of R935788 in Patients With Rheumatoid Arthritis Who Have Completed the Treatment Phase of a Rigel-Sponsored R935788 Study

Last checked: Nov 20, 2026Latest source record: Jun 25, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

624

Actual

Start

Aug 2008

Primary completion

Aug 2013

Study completion Aug 2013

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Dec 9, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this new research study is to gain additional information about how safe and effective R935788 is over a longer period of time.

Conditions

  • Rheumatoid Arthritis

Interventions

  • Fostamatinib Disodium (R935788)Drug

    50 mg PO BID; 100 mg PO BID; 100 mg PO QD; 150 mg tablet PO QD

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Patients Who Had at Least 1 Treatment Emergent Adverse Event in Any CategoryTime frame: Entry in extension to end of study, up to a maximum of 5 years. (Variable by subject - median duration of 3 years)

Locations

76 sites in 11 countries. Site status is shown where the registry gives one.

  • Research Site

    La Jolla, California

  • Research Site

    Palm Desert, California

  • Research Site

    Palo Alto, California

  • Research Site

    San Diego, California

  • Research Site

    Santa Maria, California

  • Research Site

    Hamden, Connecticut

  • Research Site

    Washington D.C., District of Columbia

  • Research Site

    Aventura, Florida

  • Research Site

    Boca Raton, Florida

  • Research Site

    Gainesville, Florida

  • Research Site

    Ocala, Florida

  • Research Site

    Orange Park, Florida

  • Research Site

    Orlando, Florida

  • Research Site

    South Miami, Florida

  • Research Site

    Venice, Florida

  • Research Site

    Boise, Idaho

  • Research Site

    Coeur d'Alene, Idaho

  • Research Site

    South Bend, Indiana

  • Research Site

    Elizabethtown, Kentucky

  • Research Site

    Cumberland, Maryland

  • Research Site

    Hagerstown, Maryland

  • Research Site

    Lansing, Michigan

  • Research Site

    Omaha, Nebraska

  • Research Site

    Roslyn, New York

  • Research Site

    Smithtown, New York

  • Research Site

    Raleigh, North Carolina

  • Research Site

    Mayfiled Village, Ohio

  • Research Site

    Erie, Pennsylvania

  • Research Site

    Willow Grove, Pennsylvania

  • Research Site

    Wyomissing, Pennsylvania

  • Research Site

    Jackson, Tennessee

  • Research Site

    Austin, Texas

  • Research Site

    San Antonio, Texas

  • Research Site

    Oklahoma City, Washington

  • Research Site

    Spokane, Washington

  • Research Site

    Antwerp, Belgium

  • Research Site

    Ghent, Belgium

  • Research Site

    Liège, Belgium

  • Research Site

    Plovdiv, Bulgaria

  • Research Site

    Rousse, Bulgaria

Showing 40 of 76 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.